Dinamo

Dinamo is a precision therapeutics company for the $230B immunology market. Today, patients cycle through drugs by trial and error, and promising candidates fail in trials too broad to show a real effect.

Dinamo's proprietary AI+epigenetic platform identifies the patients who are likely to respond to each specific drug. Epigenetics holds the key to precision immunology, and with that, unlocks hundreds of billions of dollars of value over time.

By combining that platform with a unique business model, Dinamo aims to transform immunology into precision immunology.